About Syntis
Syntis is a company based in Boston (United States) founded in 2021 by Robert Langer, Rahul Dhanda, and Giovanni Traverso.. Syntis has raised $65.88 million across 5 funding rounds from investors including NIH, Colorcon and W. R. Berkley. Syntis offers products and services including SYNT-101. Syntis operates in a competitive market with competitors including Fagron, Ignota Labs, RareStone Group, Revelation Pharma and Pharmedium, among others.
- Headquarter Boston, United States
- Founders Robert Langer, Rahul Dhanda, Giovanni Traverso
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Syntis Bio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$65.88 M (USD)
in 5 rounds
-
Latest Funding Round
$33 M (USD), Series A
Jul 01, 2025
-
Investors
NIH
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Syntis
Syntis offers a comprehensive portfolio of products and services, including SYNT-101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral treatment for obesity that mimics gastric bypass effects.
Funding Insights of Syntis
Syntis has successfully raised a total of $65.88M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $33 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $33.0M
-
First Round
First Round
(17 Aug 2022)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Grant - Syntis | Valuation |
investors |
|
| Jul, 2025 | Amount | Series A - Syntis | Valuation | Cerberus Capital Management | |
| Dec, 2024 | Amount | Series B - Syntis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Syntis
Syntis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Colorcon and W. R. Berkley. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage life sciences and tech focused VC firm investing primarily in the US
|
Founded Year | Domain | Location | |
|
Safar Partners is engaged in investing in technology startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Syntis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Syntis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Syntis Comparisons
Competitors of Syntis
Syntis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fagron, Ignota Labs, RareStone Group, Revelation Pharma and Pharmedium, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug compounding services are provided by Fagron.
|
|
| domain | founded_year | HQ Location |
AI-driven toxicity prediction tools for early-stage drug discovery scientists
|
|
| domain | founded_year | HQ Location |
Provider of network and treatments to individuals and their families affected by rare diseases drugs
|
|
| domain | founded_year | HQ Location |
A network of compounding pharmacies is operated nationwide.
|
|
| domain | founded_year | HQ Location |
Drug compounding services are provided to healthcare facilities nationwide.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Syntis
Frequently Asked Questions about Syntis
When was Syntis founded?
Syntis was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Syntis located?
Syntis is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Syntis?
Rahul Dhanda is the current CEO of Syntis. They have also founded this company.
Is Syntis a funded company?
Syntis is a funded company, having raised a total of $65.88M across 5 funding rounds to date. The company's 1st funding round was a Series B of $6.32M, raised on Aug 17, 2022.
What does Syntis do?
Syntis was founded in 2021 in Boston, United States, by co-founders Robert Langer, Rahul Dhanda, and Giovanni Traverso. The company operates within the pharmaceutical sector, where customized drug compounding services are delivered. These services involve the preparation of tailored medications to meet specific patient requirements. Focus is placed on sterile compounding processes compliant with regulatory standards, supporting healthcare providers across the region.
Who are the top competitors of Syntis?
Syntis's top competitors include Ignota Labs, Fagron and RareStone Group.
What products or services does Syntis offer?
Syntis offers SYNT-101.
Who are Syntis's investors?
Syntis has 11 investors. Key investors include NIH, Colorcon, W. R. Berkley, Cerity Partners, and Mansueto Office.